Featured Share Your Research

Tak Mak

Tak Wah Mak, OC OOnt FRS FRSC, is a Canadian medical researcher, geneticist, oncologist, and biochemist. He first became widely known for his discovery of the T-cell receptor in 1983 and pioneering work in the genetics of immunology. In 1995, Mak published a landmark paper on the discovery of the function of the immune checkpoint protein CTLA-4, thus opening the path for immunotherapy/checkpoint inhibitors as a means of cancer treatment. Mak is also the founder of Agios Pharmaceuticals, whose lead compound, IDHIFA®, was approved by the FDA for Acute myeloid leukemia in August 2017, becoming the first drug specifically targeting cancer metabolism to be used for cancer treatment. He has worked in a variety of areas including biochemistry, immunology, and cancer genetics. His groundbreaking work on the T-cell receptor has been postulated to be in consideration for a Nobel prize.

Teaching T Cells Where To Go: Immune-Derived Acetylcholine Facilitates Migration Into Infected Tissues

Most people think of acetylcholine as a neurotransmitter, a substance that is produced by nerve cells to relay signals between nerves as well as from nerves to muscle cells. In the brain, acetylcholine is linked to learning and attention. Recently, […]